T Cell Detection of a B-Cell Tropic Virus Infection: Newly-Synthesised versus Mature Viral Proteins as Antigen Sources for CD4 and CD8 Epitope Display by Mackay, Laura K. et al.
 
T Cell Detection of a B-Cell Tropic Virus Infection: Newly-
Synthesised versus Mature Viral Proteins as Antigen Sources for
CD4 and CD8 Epitope Display
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Mackay, Laura K., Heather M. Long, Jill M. Brooks, Graham S.
Taylor, Carol S. Leung, Adrienne Chen, Fred Wang, and Alan B.
Rickinson. 2009. T cell detection of a B-cell tropic virus infection:
Newly-synthesised versus mature viral proteins as antigen sources
for CD4 and CD8 epitope display. PLoS Pathogens 5(12):
e1000699.
Published Version doi:10.1371/journal.ppat.1000699
Accessed February 19, 2015 7:11:52 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:4728505
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAT Cell Detection of a B-Cell Tropic Virus Infection: Newly-
Synthesised versus Mature Viral Proteins as Antigen
Sources for CD4 and CD8 Epitope Display
Laura K. Mackay
1, Heather M. Long
1, Jill M. Brooks
1, Graham S. Taylor
1, Carol S. Leung
1, Adrienne
Chen
2, Fred Wang
2, Alan B. Rickinson
1*
1School of Cancer Sciences and MRC Centre for Immune Regulation, College of Medicine, University of Birmingham, Birmingham, United Kingdom, 2Department of
Medicine, Brigham & Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
Abstract
Viruses that naturally infect cells expressing both MHC I and MHC II molecules render themselves potentially visible to both
CD8
+ and CD4
+ T cells through the de novo expression of viral antigens. Here we use one such pathogen, the B-
lymphotropic Epstein-Barr virus (EBV), to examine the kinetics of these processes in the virally-infected cell, comparing
newly synthesised polypeptides versus the mature protein pool as viral antigen sources for MHC I- and MHC II-restricted
presentation. EBV-transformed B cell lines were established in which the expression of two cognate EBV antigens, EBNA1
and EBNA3B, could be induced and then completely suppressed by doxycycline-regulation. These cells were used as targets
for CD8
+ and CD4
+ T cell clones to a range of EBNA1 and EBNA3B epitopes. For both antigens, when synthesis was induced,
CD8 epitope display rose quickly to near maximum within 24 h, well before steady state levels of mature protein had been
reached, whereas CD4 epitope presentation was delayed by 36–48 h and rose only slowly thereafter. When antigen
expression was suppressed, despite the persistence of mature protein, CD8 epitope display fell rapidly at rates similar to
that seen for the MHC I/epitope half-life in peptide pulse-chase experiments. By contrast, CD4 epitope display persisted for
many days and, following peptide stripping, recovered well on cells in the absence of new antigen synthesis. We infer that,
in virally-infected MHC I/II-positive cells, newly-synthesised polypeptides are the dominant source of antigen feeding the
MHC I pathway, whereas the MHC II pathway is fed by the mature protein pool. Hence, newly-infected cells are rapidly
visible only to the CD8 response; by contrast, latent infections, in which viral gene expression has been extinguished yet
viral proteins persist, will remain visible to CD4
+ T cells.
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Introduction
Many intracellular pathogens, particularly viruses, naturally infect
cells of the haemopoieticsystem that express both MHC I and MHC II
molecules. Such infected cells may be rendered visible to the host T cell
response through the intracellular processing of virally-encoded
proteins, leading to cell surface display of MHC I- and MHC II-
peptide complexes recognised by CD8
+ and CD4
+ T cells respectively.
With regard to MHC I-restricted presentation, the speed with which
virus-infected cells become recognisable by CD8
+ T cells [1] and the
involvement of the proteasome in that process [2] led to the idea that a
proportion of all newly-synthesised viral polypeptides were marked for
immediate degradation, generating peptides that were fed into the
MHC I pathway [3]. While the concept has evidential support
[4,5,6,7], questions remain about the proportion of translation
products sacrificed in this way [8,9], the mechanism that underpins
their selection [10,11] and most importantly the degree to which, in
latently-infected cells where viral antigen synthesis has been extin-
guished, cells may still be visible to the virus-specific CD8 response
through MHC I-restricted processing of antigen from the mature
protein pool. Only two studies have attempted to address this latter
issue by specifically regulating antigen expression rather than resorting
to general inhibitors of translation [12,13]. Though both studies
supported the dominance of newly-synthesised protein as an antigen
source, in each case the evidence came from a single epitope studied at
a very limited number of time points leaving the generality of the
results, with respect to such variables as antigen dose, epitope location
and target cell identity, unresolved.
Less is known about the rules governing MHC II-restricted
presentation of endogenously expressed viral antigens, though it is
clear that under some circumstances this can occur [14,15]. To date
there are examples of endogenous antigen accessing the MHC II
pathway either through location in the endoplasmic reticulum itself
[16], through delivery to endosomes/lysosomes by macro- [17,18]
or chaperone-mediated [19] autophagy, or through release and re-
uptake by neighbouring cells [20]. However there is little
information on two important issues: firstly the kinetics with which
MHC II-restricted epitopes are presented following antigen
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visible to the CD4
+ T cell response, and secondly the relative
importance of newly-synthesised polypeptides and the mature
protein pool as antigen sources.
Here we address these issues using Epstein-Barr virus (EBV), a
human gamma-herpesvirus that transformsB cells in vitro intoMHC
I/II-positive lymphoblastoid cell lines (LCLs) expressing eight viral
proteins, the nuclear antigens EBNAs 1, 2 3A, 3B, 3C and -LP, and
the latent membrane proteins LMPs 1 and 2 [21]. Such LCLs
resemble the virus-transformed B cells that arise during EBV
infection in vivo and elicit the MHC I- and MHC II-restricted T cell
responses that control the infection [22]. Many of these responses
have been mapped to individual peptide epitopes and epitope-
specific CD4
+ and CD8
+ T cell clones shown to recognise MHC-
matched LCL targets [22]. Here we sought to use such clones to
follow the presentation of EBV antigens via the MHC I and MHC
II pathways in an LCL background which lacked base-line epitope
display and where expression of the cognate antigen could be
temporally controlled. For this purpose we chose two indicator
antigens, EBNA3B and EBNA1. EBNA3B is non-essential for
transformation in vitro and therefore one can establish LCLs with an
EBNA3B gene-deleted virus [23,24]; EBNA1, the virus genome
maintenance protein, is required for transformation but shows
sequence variation between virus isolates, allowing one to establish
LCLs using a virus that lacks many of the relevant T cell epitopes
[25,26]. In both cases we then introduced the cognate antigen-
coding sequence under the control of a doxycycline-regulated
promoter and monitored CD4 and CD8 epitope display after
inducing or suppressing new antigen synthesis.
Results
Characterisation of the dox-regulated expression system
using EBNA3B
Figure 1A shows the vector used to achieve dox-dependent
antigen expression [27]. Rat CD2 expression from the vector
backbone allows initial enrichment of transfected cells, while the
EBV ori-p sequence promotes episomal maintenance in LCLs.
Antigen-coding sequences lie under the control of a dox-regulated
promoter. We first introduced an EBNA3B-carrying vector
(pEBNA3B-tet, Figure 1A) into LCLs made using a recombinant
EBNA3B-KO virus. Figure 1B illustrates the pattern of results
consistently observed with stable pEBNA3B-tet transfectants on
three different LCL backgrounds. EBNA3B protein expression,
undetectable by immunoblotting in non-induced cells, showed a
clear dose-dependent response to 7 day treatment with dox,
reaching a level equivalent to that seen in wild-type EBV-
Author Summary
Many viruses infect cells in which both the MHC I and MHC
II pathways of antigen presentation are active, and so viral
proteins expressed in those cells may be presented as
MHC I-peptide complexes to CD8
+ T cells and as MHC II-
peptide complexes to CD4
+ T cells. Here we study these
processes in a model system involving Epstein-Barr virus-
infected human B lymphocytes (MHC I/II-positive) where
viral antigen expression can be induced or suppressed at
will, and antigen presentation tracked with specific CD8
+
and CD4
+ T cell clones. In this system, we find that the
MHC I pathway is entirely fed by newly-synthesised
polypeptides, whereas the MHC II pathway depends upon
antigen supplied from the mature protein pool. Hence,
while only CD8
+ T cells can rapidly recognise new
infections, only CD4
+ T cells will recognise latent infections
in which viral gene expression is extinguished yet a pool of
viral antigens remains.
Figure 1. Inducible expression of EBNA3B as an indicator antigen.
(A) Map of the pEBNA3B-tet vector, a derivative of the dox-dependent
expression vector pRTS-1 [27]. Rat CD2 (expressed as a truncated signalling-
negative surface protein) allows for selection post-transfection. oriP is the
EBV origin of plasmid replication and mediates long-term maintenance of
the vector as an episome in LCL cells. A bidirectional dox-regulated
promoter (BiTet) controls expression of the gene insert and GFP. Here the
gene insert encodes EBNA3B (grey box); T cell epitopes are located by dark
lines and identified above (CD8) or below (CD4) by three letter code. (B)
Immunoblot showing EBNA3B protein levels in a pEBNA3B-tet LCL 7 days
after dox-induction at 0–500 ng/ml; EBNA3B as expressed in a wild-type
B95.8 virus-transformed LCL (wt LCL) is shown for comparison. Actin levels
serve as a loading control. (C) 7 days post-induction, the above pEBNA3B-tet
LCL cells (A*1101, DRB3*0201-positive) were fixed and used as targets for
CD8
+and CD4
+T cell clones specific for the EBNA3B-derived IVT/A*1101 and
QAP/DRB3*0201 epitopes respectively. Recognition (mean of triplicate
values +/2 SD) is expressed as IFNc units/ml detected in assay supernatant
by ELISA. Reference targets, all from the same donor as above, were a wt LCL
and an EBNA3B-KO virus-transformed LCL (E3B-KO) with and without pre-
exposure to the relevant epitope peptide at 10
26 M. Results are
representative of three experiments. Assays involving two further
pEBNA3B-tet LCLs, CD8
+ clones to four other epitopes and CD4
+ clones to
two other epitopes gave a similar pattern of results.
doi:10.1371/journal.ppat.1000699.g001
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physiologic levels at higher dox concentrations.
We then assayed these same cells, dox-induced for 7 days, as
targets for T cell recognition. CD8
+ T cell clones were generated
against five well-defined epitopes in EBNA3B (HRC/B*2705,
RRA/B*2702; AVF/A*1101, IVT/A*1101, VEI/B*4402; posi-
tions shown in Figure 1A, see Table S1 for details). Because
EBNA3B had not been studied before as a CD4 target, we first
screened EBV-immune donors for CD4
+ T cell reactivity to an
EBNA3B peptide panel in IFNc Elispot assays, generated CD4
+ T
cell clones against three of the epitopes thus defined and
determined their MHC II restriction using standard approaches
[28,29]. These epitopes (FIE/DRB1*1501, ILR/DRB4*01 and
QAP/DRB3*0201; see Table S1) are located on the EBNA3B
sequence in Figure 1A. Figure 1C shows representative results
from such experiments, here using a pEBNA3B-tet LCL (A*1101/
DRB3*0201-positive) as a target for CD8
+ clones against the
IVT/A*1101 epitope and for CD4
+ clones against the QAP/
DRB3*0201 epitope. All such experiments included, as a positive
control target, a wild-type EBV-transformed LCL from the same
individual expressing EBNA3B from the resident EBV genome.
Target cell recognition is assayed by IFNc release after 18 h of co-
culture. There was no response to the non-induced pEBNA3B-tet
LCL by either CD8
+ or CD4
+ effectors, whereas dox-induced cells
were recognised at levels which increased in a dose-dependent
manner. For both effector populations, the recognition of target
cells exposed to 25 ng/ml dox (i.e. the dose inducing physiologic
levels of EBNA3B) was similar to that seen for the wild-type LCL,
whereas higher levels of induction increased recognition accord-
ingly. Assays with different pEBNA3B-tet LCLs, using effector
cells against the other four CD8 and two CD4 epitopes in
EBNA3B, gave very similar results (data not shown). All
subsequent studies were therefore conducted on cells induced to
express indicator antigens at physiologic (25 ng/ml dox) and at
supra-physiologic (100 ng/ml dox) levels, with similar patterns of
results obtained.
T cell recognition with time after EBNA3B induction
We first asked how quickly target cells became susceptible to
CD8
+ and CD4
+ T cell recognition following dox-induction.
Figure 2 shows one such experiment inducing the above
pEBNA3B-tet LCL at the two dox concentrations. In both cases,
expression of EBNA3B protein was detectable by immunoblotting
within 6 h of dox addition, and by 72 h had increased to reach a
Figure 2. EBNA3B protein expression and T cell recognition of target cells following dox-induction. The pEBNA3B-tet LCL (A*1101,
DRB4*01-positive) was induced with 25 ng/ml and 100 ng/ml dox for intervals up to 120 h and (A) analysed for EBNA3B protein by immunoblotting,
with wt and EBNA3B-KO LCL (E3B-KO) controls (note the different exposure times used for 25 and 100 ng/ml inductions), and (B) fixed and used as
targets, as in Figure 1C, for recognition by CD8
+ T cells specific for the IVT/A*1101 epitope and by CD4
+ T cells specific for the ILR/DRB4*01 epitope.
Recognition is shown by the black line (dox on); for reference, each assay included non-induced (no dox, open squares) and long-term-induced (lt
dox, open circles) cells from the same pEBNA3B-tet LCL. Values are means of triplicate wells with SD always ,5%. Similar results were obtained on
three occasions.
doi:10.1371/journal.ppat.1000699.g002
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type LCL) at the higher inducing dose (Figure 2A). Aliquots of the
same cells were used as targets in T cell assays, each time alongside
cells from the appropriate non-induced and long-term-induced
cultures. To examine epitope display at the precise time of harvest,
all target cells were fixed in 1% PFA before addition to the assay.
As shown in Figure 2B, while absolute levels of IFNc release were
always higher with targets given 100 ng/ml dox, the same pattern
of results was obtained following antigen induction at either dose.
Thus, recognition by CD8
+ T cells specific for the IVT/A*1101
epitope was detectable within 6 h of dox induction and by 36 h
had increased to plateau at the same level as seen against long-
term dox-induced targets. In contrast, recognition by CD4
+ T cells
specific for the ILR/DRB4*01 epitope was not detectable until
36–48 h and increased quite slowly thereafter, only reaching the
long-term dox plateau level on targets induced for 168 h. In
further experiments with this and other pEBNA3B-tet LCLs, these
temporal differences between CD8 and CD4 epitope display held
true for all eight EBNA3B epitopes tested (data not shown).
T cell recognition with time after EBNA1 induction
The existence of EBNA1 sequence variation between geo-
graphically distinct EBV isolates [26] allowed us to generate LCLs
using a Chinese virus strain (CKL) with epitope mutations that, for
the T cell clones used in these experiments, abrogated CD8
recognition and reduced CD4 recognition to a very low base-line.
Into these LCLs, we then introduced an epitope-positive EBNA1
allele under dox-regulated control. As shown in Figure 3, we used
both a full length EBNA1 sequence and a sequence (E1dGA) from
which the internal glycine-alanine repeat (GAr) domain had been
deleted. Note that this GAr domain reportedly offers the wild-type
protein some level of protection from CD8
+ T cell recognition
through reducing the rate of its translation from mRNA [30] and/
or though stabilising the protein from proteasomal digestion [31].
Figure 3. EBNA1 protein expression and T cell recognition of target cells following dox-induction. (A, B) CKL virus-transformed LCLs
stably transfected with either (A) the pEBNA1-tet vector encoding a full length B95.8 EBNA1 protein, or (B) the pE1dGA-tet vector encoding a GAr-
deleted B95.8 EBNA1 protein; CD8
+ and CD4
+ T cell epitopes are shown as in Figure 1A. IH4 immunoblots show protein expression following
induction for intervals of up to 120 h with 100 ng/ml dox. B95.8 and CKL virus-transformed LCLs serve as controls; note that CKL virus-coded EBNA1 is
not recognised by the IH4 antibody. (C, D) Following dox-induction as above, the pEBNA1-tet- and pE1dGA-tet LCLs (both B*3501, DRB1*11-positive)
were fixed and used as targets for CD8
+ T cells specific for the HPV/B*3501 epitope and by CD4
+ T cells specific for the VYG/DRB1*11 epitope, as in
Figure 1C. Recognition is shown by the black line (dox on); each assay included the appropriate non-induced (no dox, open squares) and long-term-
induced (lt dox, open circles) cells. Note that CKL virus-coded EBNA1 is not recognised by HPV-specific CD8
+ T cells and is barely recognised by VYG-
specific CD4
+ T cells. Values are means of triplicate wells with SD always ,5%. Similar results were obtained on three occasions.
doi:10.1371/journal.ppat.1000699.g003
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induced in the pEBNA1-tet and pE1dGA-tet LCLs following
100 ng/ml dox induction. As with inducible EBNA3B, the two
forms of EBNA1 accumulated to reach their steady state levels by
72–96 h post-induction, though E1dGA was detectable slightly
earlier than full length EBNA1 (6 versus 12 h post-induction), and
accumulated to slightly higher steady-state levels, a finding
consistent with published data [30,32].
We examined the kinetics of EBNA1 and E1dGA presentation
using clones against two CD8
+ (HPV/B*3501 and IPQ/B*07) and
two CD4
+ (GLR/DQB1*06 and VYG/DRB1*11) T cell epitopes
(see Table S1). Results from one such set of assays are shown in
Figures 3C and D, using HPV- and VYG-specific effectors and target
LCLs established from a B*3501, DRB1*11-positive donor. Focusing
first on the CD8
+T cell data, we found that both EBNA1 and E1dGA
were rapidly recognised by CD8
+ T cells and reached their plateau
values (shown by long-term induced cells) within 48 h. Note that these
plateau values were always some 20–30% higher with target cells
expressing the E1dGA construct. Given the reported effect of the GAr
domain on MHC I processing, we looked in greater detail at early
time points in the above experiment, repeating the CD8 assays hourly
overthefirst 12 hrpost-induction.As illustrated inFigure S1forassays
conducted with 25 and 100 ng/ml dox inductions, we found that
CD8 epitope display from E1dGA was indeed slightly accelerated at
early times, typically reaching 35% of its plateau value by 12 hr
compared to 25–30% for full length EBNA1. Turning now to the
CD4
+ T cell data in Figures 3C and D, antigen presentation by the
MHC II pathway was again profoundly delayed. Thus there was no
CD4
+ T cell recognition of dox-induced target LCLs (other than very
weak base-line recognition of the CKL virus-coded EBNA1) until
48 h post-induction, followed by a slow rise that did not reach the
long-term plateau value even by 168 h. Both the EBNA1 and E1dGA
proteins gave similar results in this respect, although here the plateau
level of CD4
+ T cell recognition was always slightly higher with cells
expressing the full length protein. Experiments conducted on a
different pair of pEBNA1-tet and pE1dGA-tet LCLs using T cell
clones specific for the IPQ/B*07 and GLR/DQB1*06 epitopes gave
the same pattern of results (data not shown).
The temporal differences between CD8 and CD4 epitope display
therefore held true for all epitopes studied both in EBNA3B and in
EBNA1. However we reasoned that the delayed presentation of CD4
epitopes might simply reflect their processing by an indirect route if, as
previously shown for EBNA3A and 3C, the source antigens access the
MHC II pathway through antigen release and uptake by neighbour-
ing cells in the LCL culture [20]. We first investigated this for
EBNA3B by co-cultivating ‘‘antigen donor’’ cells (a pEBNA3B-tet
LCL lacking relevant MHC restriction alleles but dox-induced to
express cognate antigen) with ‘‘antigen-recipient’’ cells (an antigen-
negative EBNA3B-KO LCL with the relevant MHC alleles) for 7
days, then used this mixture as a target for EBNA3B-specific CD4
+
and CD8
+ T cell clones. As shown in Figure S2A, we found that co-
culture could indeed sensitise recipient cells to recognition by CD4
+ T
cell clones specific for the EBNA3B ILR epitope, although not by the
corresponding CD8
+ IVT clones. However, in parallel experiments
where we co-cultured dox-induced pEBNA1-tet ‘‘antigen donor’’ cells
with a CKL virus-transformed ‘‘antigen recipient’’ LCL, there was
never any recognition of the co-culture by EBNA1-specific CD4
+ T
cells (Figure S2B). Furthermore a second sensitive method of detecting
inter-cellular antigen transfer, where recipient cells are fed with 25x-
concentrated culture supernatant from donor LCLs [20], again never
sensitised recipient cellsto EBNA1-specific effectors (Figure S2C). This
clearly shows that inter-cellular antigen transfer likely contributes to
EBNA3B’s presentation via the MHC II pathway in LCL cells;
however, as others have also observed [17], endogenously expressed
EBNA1 is presented byan intracellular route. Yet, irrespective of these
differences, both antigens show delayed presentation via the MHC II
pathway following the induction of antigen synthesis.
We therefore sought reassurance that this slow presentation did
not simply reflect an intrinsic feature of MHC class II maturation
and epitope display in our LCL cells. To do so, we used the
inducible vector system to express E1dGA fused with an invariant
chain (Ii) tag that delivers the protein directly into endosomes and
the MHC II processing compartment [33]. As shown in Figure 4A,
expression of the E1dGA-Ii protein is detectable by immunoblot-
ting 24, 48 and 72 h after 100 ng/ml dox-induction but at very
low levels compared to non-tagged EBNA1 and E1dGA. This
reflects on-going degradation of the endosomally-targeted E1dGA-
Ii protein, since adding chloroquine, an inhibitor of endosomal
proteolysis, 24 h prior to harvest increased the level of protein
detectable. Figure 4B shows the corresponding T cell assay data
following dox-induction. The Ii-tagged protein was rapidly
presented not just to CD8
+ T cells, where it was processed as
quickly as the non-targeted constructs, but also to CD4
+ T cells. In
this latter case, recognition appeared within 12 h and became
Figure 4. Ii-tagged E1dGA protein expression and T cell
recognition of target cells following dox-induction. (A) IH4
immunoblots show EBNA1 protein expression in the pE1dGA-Ii-tet LCL
at 24, 48 and 72 h post-induction with 100 ng/ml dox, with or without
chloroquine (chq) for the last 24 h before harvest. Controls are the non-
induced pE1dGA-Ii-tet LCL (time 0 h) and the pEBNA1-tet and pE1dGA-
tet LCLs (as in Figure 3) maintained in long-term dox. (B) Non-induced
cultures of the above LCLs (all B*3501, DRB1*11-positive) were induced
with 100 ng/ml dox for up to 168 h and assayed for recognition by
CD8
+ T cells specific for the HPV/B*3501 epitope and by CD4
+ T cells
specific for the VYG/DRB1*11 epitope, as in Figure 3C. Results are
shown for the pEBNA1-tet LCL (black line), pE1dGA-tet LCL (grey line)
and pIi-E1dGA-tet LCL (red line). Values are means of triplicate wells
with SD always ,5%. Similar results were obtained on three occasions.
doi:10.1371/journal.ppat.1000699.g004
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proteins. Thus our LCLs can rapidly process and present
endogenously expressed antigen, once that antigen gains access
to the MHC II presentation pathway.
T cell recognition with time after down-regulation of
antigen synthesis
We then examined antigen presentation in long-term 100 ng/
ml dox-induced cells after switching off new antigen synthesis by
dox-withdrawal. As illustrated in Figure 5A, using a Q-RT-PCR
assay for vector-encoded EBNA3B mRNA transcripts, we first
showed that .80% of transcripts are lost within 6 h and none are
detectable by 24 h. This implies that new antigen synthesis must
terminate quite rapidly after dox withdrawal. However, as shown
in Figure 5B, the EBNA3B protein is clearly very stable since it
remained easily detectable in immunoblots for several days post-
withdrawal. Indeed, as the immunoblots were loaded with equal
number of cells each time, the falling EBNA3B levels reflect both
slow natural turnover of the protein and also dilution from cell
doubling (in cultures with a doubling time of 48–72 hr).
Aliquots of LCL cells from the same experiment (HLA B*2702,
DRB3*0201-positive) were used in parallel as targets for EBNA3B-
specific T cells. As shown in Figure 5C, target cell recognition by an
RRA epitope-specific CD8
+ T cell clone fell progressively after dox
withdrawal, down to half of the original level by 48 h, to ,10% by
96 h and approaching zero thereafter. By contrast, recognition by a
CD4
+ T cell clone against the QAP epitope fell much more slowly,
being still .50% of the original level after 96 h and .20% even after
192 h. Indeed the rate of fall in CD4 epitope display closely paralleled
the level of EBNA3B protein detectable in these target cells by
immunoblotting (cf. Figures 5B and 5C). Such experiments were
conducted on all three pEBNA3B-tet LCL backgrounds, whether first
induced at 25 ng/ml or 100 ng/ml dox, and included clones against
five CD8 epitopes and three CD4 epitopes. In each case CD8
+ Tc e l l
recognition had fallen to ,10% of its original value by 96 h after dox
withdrawal, whereas CD4
+T cell recognition wasstill at 35–50% of its
original value at the much later time of 168 h (data not shown).
Results from a corresponding experiment involving pEBNA1-tet
and pE1dGA-tet LCLs are shown in Figure 6. Q-RT-PCR assays
using primer/probe combinations specific for vector-encoded
EBNA1 and E1dGA mRNAs showed mRNA levels fell rapidly
after dox-withdrawal and were undetectable beyond 12 h
(Figure 6A). Again, therefore, new antigen synthesis must rapidly
terminate following dox withdrawal yet, as shown by the
immunoblots in Figures 6B and 6D, both the EBNA1 and
E1dGA proteins are relatively stable, levels per cell falling slowly
over time and being still detectable at 168 h. When these same dox-
withdrawn cells (HLA B*3501, DRB1*11-positive) were used as
targets in T cell assays, recognition by HPV-specific CD8
+ T cells
fell to ,50% of the original level by 48 h and was undetectable by
120 h, whereas recognition by a VYG-specific CD4
+ T cells fell
much more slowly, being still 30–40% of the original value as late as
168 h. Again, parallel experiments using a different LCL back-
ground and T cell clones against the other CD8 and CD4 epitopes
in EBNA1 produced a very similar pattern of results.
Persistence of T cell recognition, the half-life of pre-
existing epitope complexes and the continued supply of
complexes from intracellular sources
While Figures 5 and 6 showed that CD8 and CD4 epitope
display fell at different rates after switching off new antigen
synthesis, in both cases target cells remained susceptible to T cell
recognition for some time. We therefore asked how the observed
rates of fall compared to the half-lives of pre-existing MHC I-
peptide and MHC II-peptide complexes on the LCL surface. Thus
pEBNA3B-tet and pEBNA1-tet LCLs of the appropriate MHC
type maintained in the absence of dox were briefly exposed to a
non- saturating dose of epitope peptide, washed well (time 0 h) and
the subsequent fall in epitope display tracked over time by T cell
assay. For comparison, all experiments included long-term-
induced cultures of the same LCLs, from which dox was either
withdrawn at time 0 h or maintained throughout. Figure 7 shows
representative data obtained for pairs of epitopes from EBNA3B
and from EBNA1. Both CD8 epitopes had half-lives on the LCL
surface of 36–48 h; indeed the rate with which exogenously loaded
CD8 peptides disappeared from the surface was only slightly faster
Figure 5. EBNA3B protein expression and T cell recognition of
transfected lines following dox-removal. (A) Q-RT-PCR assay of
EBNA3B-specific transcript levels (mean of duplicate values +/2SD) in a
long-term dox-induced (100 ng/ml) pEBNA3B-tet LCL following dox
removal, expressed relative to the level before dox removal. Controls
are an EBNA3B-KO virus-transformed LCL (E3B-KO) and the non-induced
pEBNA3B-tet LCL (no-dox). (B) Immunoblot showing EBNA3B protein
levels in a long-term dox-induced pEBNA3B-tet LCL up to 216 h after
dox-removal. Controls are an EBNA3B-KO virus-transformed LCL (E3B-
KO) and the non-induced pEBNA3B-tet LCL (no-dox). (C) At different
times following removal from 100 ng/ml dox, the above pEBNA3B-tet
LCL (B*2702, DRB3*0201-positive) was fixed and assayed for recognition
by CD8
+ T cells specific for the RRA/B*2702 epitope and by CD4
+ T cells
specific for the QAP/DRB3*0201 epitope. Recognition at each time
point is shown by the black line. Each assay included long-term-induced
cells as a control (lt dox, grey line). Values are means of triplicate wells
with SD always ,5%. Similar results were obtained on three occasions.
doi:10.1371/journal.ppat.1000699.g005
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of new antigen synthesis. However, both CD4 epitopes also had
half-lives in the same range, the levels of display on peptide-pulsed
cells therefore falling much quicker than seen on pEBNA3B-tet
and pEBNA1-tet LCL cells after cessation of antigen synthesis. A
similar pattern of results was observed for all CD8
+ and CD4
+ T
cell epitopes tested (see for example Figure S3). Such results
strongly suggest that, after the cessation of antigen synthesis, new
CD4 epitope complexes continue to reach the cell surface whereas
the supply of new CD8 epitope complexes is rapidly curtailed.
Figure 6. EBNA1 protein expression and T cell recognition of
transfected lines following dox removal. (A) Q-RT-PCR assay of
vector-expressed EBNA1 and E1dGA transcript levels (mean of duplicate
values +/2SD), in long-term dox-induced (100 ng/ml) pEBNA1-tet and
pE1dGA-tet LCLs respectively, following the removal of dox; results
expressed as in Figure 5A. (B) Immunoblot showing EBNA1 protein
levels in a long-term dox-induced pEBNA1-tet LCL up to 192 h
following removal from 100 ng/ml dox. Controls are B95.8 and CKL
virus-transformed LCLs, and the non-induced pEBNA1-tet LCL. (C)
Shown below are results of T cell assays where, at different times
following dox-removal, the above pEBNA1-tet LCL (B*3501, DRB1*11-
positive) was fixed and assayed for recognition by CD8
+ T cells specific
for the HPV/B*3501 epitope and by CD4
+ T cells specific for the VYG/
DRB1*11 epitope. Recognition is shown by the black line. Each assay
included long-term-induced cells as a control (lt dox, grey line). (D, E)
Parallel results to those shown in B, C above, using the corresponding
pE1dGA-tet LCL. Values are means of triplicate wells with SD always
,5%. Similar results were obtained on three occasions.
doi:10.1371/journal.ppat.1000699.g006
Figure 7. Half-life of MHC-peptide complexes on the cell
surface in relation to T cell recognition of transfected lines
following dox removal. (A) Results from T cell assays in which an
EBNA3B-KO virus-transformed LCL (B*2702, DRB4*01-positive) was
loaded with the relevant EBNA3B epitope peptide at a concentration
mediating half-maximal recognition, washed well and then used as a
target, either immediately (0 h) or up to 192 h later, with CD8
+ T cells
specific for the RRA/B*2702 epitope (left) or CD4
+ T cells specific for the
ILR/DRB4*01 epitope (right). Targets were fixed immediately before the
assay. Levels of recognition, expressed as a percentage of that seen at
time 0 h, are shown by the red line. In parallel, the same T cells were
assayed against a long-term dox-induced pE3B-tet LCL, from the same
donor as above, either left in dox throughout the experiment (lt-dox,
grey line) or removed from dox at time 0 h (black line). (B) Results from
the corresponding experiment using a CKL virus-transformed LCL
(B*3501, DRB1*11-positive) loaded with the relevant EBNA1 epitope
peptides and assayed using CD8
+ T cells specific for the HPV/B*3501
epitope (left) or CD4
+ T cells specific for the VYG/DRB1*11 epitope
(right). Results (red line) are shown as above. Parallel assays were carried
out on a long-term dox-induced pEBNA1-tet LCL from the same donor,
either left in dox (lt-dox, grey line) or dox-depleted at time 0 h (black
line) as above. Similar results were obtained on three occasions.
doi:10.1371/journal.ppat.1000699.g007
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citrate/phosphate buffer at pH 3.1) that efficiently strips pre-
existing EBV epitope/MHC I and/MHC II complexes from the
LCL surface without affecting cell viability. Having switched off
antigen synthesis in pEBNA3B-tet and pEBNA1-tet LCLs by dox
withdrawal, we followed the recovery of epitope peptide display by
T cell recognition, stripping pre-existing epitopes off the cell surface
either at the time of dox withdrawal (time 0 h) or 48 h later. The
results from such assays are illustrated in Figure 8, again comparing
CD8/CD4 epitope pairs from EBNA3B and from EBNA1. In each
case, new epitope supply after stripping at time 0 h (blue line) or
48 h (red line) is shown against the level of surface epitope display
seen on the same target cells that had been similarly dox-depleted at
time 0 h but not stripped (black line). The CD8 epitopes showed
significant recovery of cell surface display 24 h after stripping at
time 0 h but then levels fell away rapidly, down to the same low
values remaining on dox-depleted, non-stripped cells. When
stripping was delayed until 48 h after dox-withdrawal, there was
only a small recovery of CD8 epitope display, recapitulating the low
residual values on non-stripped cells. By contrast, the CD4 epitopes
showed a substantial recovery whether the cells were stripped at 0 h
or 48 h following dox-withdrawal. Furthermore the recovery was
sustained for up to 192 h, with stripped cells regaining the same
persistent levels of CD4 epitope display as shown by non-stripped
cells. Figure S4 shows the results of a similar experiment involving
different target LCLs, here initially induced at 25 ng/ml dox, and
effectors against different epitopes. This emphasises the point that
consistent results were obtained for all CD8/CD4 epitope pairs
tested, whether antigen was initially expressed at physiological or
supra-physiological levels.
Discussion
Here we address a generic question regarding pathogens,
particularly viruses, that naturally infect target cells in which both
the MHC I and MHC II pathways of antigen presentation are active.
Antigens endogenously expressed within such an infected cell could
potentially be presented by both pathways, rendering the cell visible
to CD4
+ as well as CD8
+ T cells. However, the relative timing of
those events and their degrees of dependence upon new antigen
synthesis have never been rigorously examined in parallel. Our
experimental system, based on EBV-infected B cell lines and the
regulatable expression of EBV antigens, allows one to study these
processes in a physiologically relevant cell context, select appropriate
levels of antigen expression and track the presentation of CD8 and
CD4 epitopes from the same source antigen after inducing or
suppressing antigen synthesis. We studied five CD8 and three newly-
defined CD4 epitopes from EBNA3B and two CD8 and two CD4
epitopes from EBNA1, in each case probing epitope display with at
least two independent clones per epitope. To cover the wide range of
MHC restricting alleles involved, assays were conducted on three
different pEBNA3B-tet LCLs and two different pairs of pEBNA1-tet
and pE1dGA-tet LCLs. The contrasting patterns of CD8 versus CD4
epitope display were remarkably consistent across the whole range of
epitopes and antigens studied, and were reproducible whether the
antigen was being expressed at physiologic (LCL-like) or supra-
physiologic levels. We infer that these differences are not chance
consequences of particular epitope selection but reflect fundamental
differences in the way that endogenously expressed viral antigens are
handled by the MHC I and MHC II presentation pathways in
human B cells. At the same time, we would emphasise that both
EBNA3B and EBNA1 are native nuclear proteins; there could
possibly be differences in detail were one to study the processing of
viral antigens normally resident in the cytoplasm or marked for
export, but we would nevertheless expect the basic pattern of results
to remain the same.
With antigen induction, we found that EBNA3B and both forms
of EBNA1 were rapidly recognised by CD8
+ T cells. Recognition
was first apparent soon after dox addition and rose to almost
maximal levels within 24 h, well before steady-state levels of these
proteins, as detected by immunoblotting, were reached. The
results with EBNA1 were particularly interesting given the history
of work on this protein as a target for CD8
+ T cells. Thus early
studies found that the GAr domain was able to protect EBNA1
from presentation via the MHC I pathway [31] and that this was
associated with resistance to proteasomal degradation [31,34].
However, more recent results have shown that this protection from
CD8
+ T cell recognition is only partial [35,36,37,38] and may
Figure 8. Recovery of T cell recognition of transfected lines
following dox removal and stripping of cell surface peptides.
(A) Results from T cell assays in which a long-term dox-induced
pEBNA3B-tet LCL (B*4402, DRB3*0201-positive) was washed free of dox,
and used, either immediately (time 0 h) or up to 192 h later, as targets
for a CD8
+ T cell clone specific for the VEI/B*4402 epitope (left) or a
CD4
+ T cell clone specific for the QAP/DRB3*0201 epitope (right).
Results are shown for cells stripped of cell surface peptides either
immediately after dox removal (0 h, blue line) or 48 h later (red line),
then re-cultured. Targets were fixed immediately before the assay.
Results for parallel cultures of non-stripped target cells, either left in dox
(lt-dox, grey line) or removed from dox at time 0 h (black line) are
shown for comparison. (B) Results from a corresponding experiment
using a long-term dox-induced pEBNA1-tet LCL (B*07, DQB1*06-
positive) as a target for recognition by a CD8
+ T cell clone specific for
the IPQ/B*07 epitope (left) or a CD4
+ T cell clone specific for the GLR/
DQB1*06 epitope (right). Values are means of triplicate wells with SD
always ,5%. Similar results were obtained on three occasions.
doi:10.1371/journal.ppat.1000699.g008
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rather than of sensitivity to the proteasome per se [30,32,39,40].
Importantly, many of these studies involved chimaeric antigen
constructs, often with indicator epitope insertions, tested in in vitro
translation or transient transfection assays, leaving the effects of
the GAr domain in its physiologic setting open to question. In the
present work we found that, after inducing antigen synthesis,
E1dGA was presented to CD8
+ T cells slightly quicker than the
wild-type protein, though the magnitude of the effect was not as
great as noted in other less physiologic experimental settings. We
believe that our system is robust in this regard since we also found
that CD8
+ T cell recognition of cells induced to express E1dGA
long-term was consistently 20–30% greater than seen with cells
induced to express EBNA1. This exactly mirrors levels of EBNA1
epitope display seen earlier in LCLs transformed with EBV
expressing a GAr-deleted EBNA1 protein versus LCLs trans-
formed with wild-type virus [35].
Overall the results of the antigen induction experiments were
consistent with MHC I presentation of newly synthesised polypeptides.
However,inthesame experiments,the MHC II-restricted presentation
of EBNA3B and EBNA1 was grossly delayed; CD4 epitope display
only became detectable after 36–48 h and took some 7 days to reach
the long-term steady state level. This delay is not an intrinsic feature of
MHC II processing in LCL cells since an invariant chain-targeted
E1dGA protein expressed in the same dox-inducible system was
detected by CD4
+ T cells within 12 h and maximum recognition was
reached within 48 h. This reinforces a large amount of earlier evidence
testifying to the efficiency of MHC II antigen processing in LCL cells
[41]. Our findings therefore imply that endogenously expressed
antigens such as EBNA3B and EBNA1 are delivered very slowly into
the MHC II processing pathway, even though they may access that
pathway by different routes. Thus co-cultivation experiments showed
that EBNA3B (like EBNA3A and 3C,[20])is processed, at least in part,
via the inter-cellular transfer of antigen between LCL cells. The precise
form of antigen being transferred in LCL cultures is not known, except
that it clearly requires active processing and, by analogy with our
earlier work using donor cells transformed with a replication-defective
EBV strain [20], does not derive from cells dying as a result of lytic
virus replication. By contrast, the same experimental approaches never
detected any evidence for inter-cellular transfer of EBNA1. Thus the
CD4 epitopes recognised by our EBNA1-specific T cell clones must
derive from antigen processed by an intracellular route. In that regard,
others have also observed that endogenously expressed EBNA1 is
processed intracellularly in LCL cells, and have suggested the
involvement of autophagy in that process [17].
Dox-withdrawal from pre-induced LCLs allowed us to ask whether,
in the absence of new antigen synthesis, the pre-formed intracellular
p o o lo fm a t u r ep r o t e i nc a nf e e dt h eM H CIa n dM H CI Ip a t h w a y s .
We first verified that gene transcription from the dox-inducible
promoter terminated rapidly after dox-withdrawal, with EBNA3B and
EBNA1 transcript levels falling by .8 0 %w i t h i n6ha n db e c o m i n g
undetectable by 12-24 h. New antigen synthesis must therefore be
curtailed at least at the same rate yet, as is clear from the immunoblots,
the pre-formed EBNA3B, EBNA1 and E1dGA proteins remain
detectable for days thereafter. In this regard the natural turnover of
EBNA3B has not been investigated previously, while ours is the first
attempt to compare turnover of the EBNA1 and E1dGA proteins
having switched off their synthesis specifically, rather than non-
specifically with general protein synthesis inhibitors. Previous studies of
the latter kind, where EBNA1 is first expressed by transient
transfection or from recombinant viral vectors, all indicate that the
wild-type protein has a long half-life, but differ in the degree to which
this is shortened by GAr deletion [31,32,36,42]. Our finding, that in
the natural setting of the LCL cell both EBNA1 and E1dGA are stable
proteins, accords with the most recent findings from transiently
transfected cells with protein synthesis inhibitors [42]. For our present
purpose, however, the essential point is that both EBNA3B and the
two forms of EBNA1 are sufficiently stable that a large pool of mature
protein persists in the cells for several days after the cessation of new
antigen synthesis, providing a source of antigen that is potentially
a v a i l a b l et ob o t hM H CIa n dM H CI Ip r e s e n t a t i o np a t h w a y s .
It is therefore significant that, upond o x - w i t h d r a w a l ,Tc e l la s s a y s
showed a marked fall in cell surface display of all seven CD8 epitopes
tested, typically to ,50% of the initial level by 48 h and to ,10% by
96 h. Indeed the rate of fall was in each case close to that seen when the
corresponding epitope-negative LCL cells were loaded with epitope
peptide at non-saturating levels and tracked over time to follow the
natural half-life of the MHC I-peptide complex on the cell surface.
These half-life measurements accord with earlier work, for example the
RRA/B*2702 epitope from EBNA3B was estimated to have a half-life
of 40 h in the present T cell assays and of 37 h in earlier antibody-
based assays [43]. While rates of fall were similar on dox-depleted and
peptide-pulsed cells, there was often a slight delay in the timing of that
fall on dox-depleted cells. At least part of this lag must reflect the fact
that, for a short time after dox-withdrawal, new MHC-peptide
complexes either already in the export pathway or generated from
residual mRNA translation will be delivered to the cell surface. Overall,
the results strongly suggest that continued CD8 epitope display
depends upon continued antigen synthesis. By contrast, T cell
recognition of CD4 epitopes consistently fell much more slowly after
dox-withdrawal, typically being still .50% of the initial level at 96 h
and still easily detectable as late as 192 h. Recognition persisted despite
the fact that in peptide pulsing experiments the relevant MHC II/CD4
epitope complexes have half-lives similar to their MHC I/CD8 epitope
counterparts, strongly implying that the MHC II presentation pathway
was being fed from the mature protein pool.
These conclusions were further supported by experiments in
which cells were stripped of cell surface peptides after dox-
withdrawal, and then assayed for the recovery of epitope display
over time. Interestingly, cells stripped immediately after dox
withdrawal showed a significant recovery of detection by CD8
+ T
cells 24 h later; however this effect, which could be quite marked
for some epitopes, was transient with recognition falling away at
later times. We attribute this transient recovery to the continued
supply of newly-formed complexes to the cell surface occurring
immediately after dox-withdrawal (as above) and possibly also to
the reappearance of pre-existing mature complexes that were
recycling from the surface at the time of stripping [44].
Importantly, cells stripped 48 h after dox removal, by which time
surface epitope display was declining rapidly, showed minimal
recovery of CD8 recognition. This strongly suggests that the
mature protein pool, which is still substantial in cells 48 h after
dox-withdrawal, makes little if any contribution to the MHC I
presentation pathway. By contrast, CD4 epitope display was
extensive and prolonged, whether cells were stripped immediately
after dox-withdrawal or 48 h later. Such sustained presentation of
CD4 epitopes by cells in which de novo synthesis of EBNA3B,
EBNA1 and E1dGA was terminated 48 h earlier must reflect
processing of antigen derived from the mature protein pool.
In summary, we find that in virally-infected human B cells newly-
synthesised viral polypeptides, by inference rapidly degraded
translation products, are the dominant source of antigen feeding
the MHC class I pathway. This does not discount the possibility that
the mature protein pool may, in other circumstances or in other cell
types, contribute to such a role. Indeed, prompted by a report that
irradiation could increase MHC I processing activity in cyclohexi-
mide-treated cells[45], we irradiated pEBNA3B-tet and pEBNA1-tet
LCLsseveraldaysafter dox-withdrawal and showeda small, transient
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synthesis, must have come from mature protein (L.K. Mackay,
unpublished observations). However we find no evidence of any
major contribution to the MHC I pathway from this source in a
naturally proliferating LCL cell. By contrast, in these same cells
endogenous antigen presentation via the MHC II pathway is
dependent upon the mature protein pool and shows no immediate
connection with the presence or absence of de novo translation
products.Thesefundamental differences have important implications
for virus-specific CD8
+ and CD4
+ T cells as direct effectors against
infections of MHC I/II-positive target cells. In such circumstances,
only CD8
+ T cells have the capacity to recognise newly infected cells
as soon as de novo antigen synthesis begins; CD4
+ T cell recognition
will be delayed until the intracellular antigen pool has increased
sufficiently to feed the MHC II presentation pathway. Interestingly
however, our results imply that for viruses establishing latent
infections in MHC I/II-positive cells where viral gene expression is
extinguished but whereviral proteins persist, a situation that could for
example pertain to gamma-herpesviruses and their genome mainte-
nance proteins, the latently-infected cell reservoir may remain visible
to CD4
+ Tc e l l s .
Materials and Methods
Ethics statement
All experiments were approved by the South Birmingham Local
Research Ethics Committee (07/Q2702/24). All patients provided
written informed consent for the collection of blood samples and
subsequent analysis.
Stable transfection and establishment of pEBNA-tet cell lines
LCLs were established using the reference EBV strain B95.8, a
B95.8-based recombinant lacking the EBNA3B gene (EBNA3B-
KO) [23], or the Chinese CKL strain (called NPC 15, [46]) with a
variant EBNA1 sequence. All lines were maintained in RPMI 1640
medium supplemented with 2 mM glutamine and 10% fetal calf
serum (standard medium). A derivative of the dox-dependent
expression vector pRTS-1 [27] and the EBNA3B, EBNA1 and
E1dGA constructs were kindly provided by Dr J Mautner, Munich;
in cases where EBNA1 was expressed under dox control, a
derivative of pRTS-1 lacking constitutively expressed EBNA1 was
used. Ii-tagged E1dGA and FLAG-tagged EBNA1 and E1dGA
constructs were constructed by PCR, verified by DNA sequencing,
then introduced into the vector by standard DNA cloning
procedures. To introduce these into LCLs, DNA (15 mg) was
transfected into 10
7 cells by electroporation in 300 ml Optimem
(Invitrogen) at 230 V and 960 mF using a Biorad electroporation
apparatus. Immediately after electroporation, cells were resus-
pended in RPMI 10% FCS and were incubated at 37uCa n d5 %
CO2. After 24 h in culture, cells were then stained with rat CD2-
specific antibody OX34 and were positively selected by magnetic
cell sorting with anti-mouse IgG2a/b Microbeads and LS columns
(Miltenyi Biotech) according to the manufacturer’s guidelines. Cells
were then expanded and maintained in culture in the absence of
dox, before testing for dox- inducibility of antigen expression.
Quantitative real-time reverse transcription (Q-RT) PCR
Total RNA was extracted from 5610
6 cells using a Nucleospin
RNA extraction kit (Macherery Nagel) according to the manu-
facturer’s instructions. 400 ng RNA was reverse transcribed into
cDNA using a pool of primers specific for EBNA3B, EBNA1/
E1dGA and (as an internal control) cellular GAPDH transcripts.
In subsequent quantitative PCR (Q-PCR) assays, primer/probe
combinations were used to amplify (i) the 39 end of the major
EBNA3B exon, or (ii) the unique 59 end of EBNA1/E1dGA
transcripts initiated from the dox-regulatable promoter in plasmid
pEBNA-tet. After normalising to GAPDH expression, levels of
EBNA3B or EBNA1/E1dGA transcription in test cells are
expressed relative to that of a fully induced cell line.
Western blot analysis
Cells were sonicated in UTB buffer (8 M urea, 150 mM b-
mercaptoethanol, 50 mM Tris/HCl pH 7.5) and cellular debris
removed by centrifugation. Protein concentration was determined by
using the BioRad Bradford Protein determination reagent. Solubi-
lized proteins were separated by 8% SDS-PAGE and transferred to
nitrocellulose membranes (Thermo Scientific Pierce). Cellular and
viral proteins were detected by incubating the membranes with
specific Abs followed by HRP-conjugated secondary Abs (Sigma).
Bound HRP was visualized using the ECL-plus detection kit
(Amersham Biosciences). Antibodies used include: anti-EBNA3B
(ExAlpha), anti-EBNA1 (IH4, [47]), and anti-actin (Sigma).
Epitope-specific T cell clones
CD4 epitope peptides within EBNA3B were identified by screening
immune donor lymphocytes in IFNc Elispot assays on peptide panels
(20-mers overlapping by 15) covering the primary sequence of B95.8
strain EBNA3B. All peptides were synthesized using 9-fluorenyl-
methoxycarbonyl chemistry (Alta Bioscience; University of Birming-
ham, Birmingham, U.K.), dissolved in DMSO, and concentrations
were determined by biuret assay. CD4
+ and CD8
+ Tc e l lc l o n e s
specific for these and for other defined epitopes within EBNA 1 or
EBNA3B were generated as described [29]. All epitope sequences are
shown, with their MHC restricting alleles, in Table S1.
Assays of target cell recognition
Immediately before all T cell assays, target LCL cells were fixed
in 1% paraformadehyde for 10 min followed by quenching with
0.2 M glycine for 10 min, and then washed with PBS before
resuspension in standard medium. Assays therefore measured the
level of epitope display at a defined time point, with no further
changes occurring during the 18 h assay period itself. Unless
otherwise stated, fixed target cells were seeded at 10
5 cells per
triplicate assay well, to which 2000 T cells were added; after 18 h
incubation, supernatant medium was harvested and assayed for
IFNc release by ELISA (Endogen). Assays routinely included the
following control targets: the wild-type B95.8 virus-transformed
LCL from the same donor as the pEBNA-tet-transfected LCLs, the
relevant pEBNA-tet-transfected LCL both without dox induction
and long-term dox-induced, and the pEBNA-tet-transfected LCL
without dox-induction but exogenously loaded with 10
27 M
concentration of the relevant epitope peptide. In all assays, at least
two different T cell clones were tested for each epitope specificity.
Peptide half-life and peptide stripping assays
In assays measuring the half-life of peptide/MHC complexes at
the cell surface, LCLs with relevant HLA types but transformed
with EBNA3B-KO or CKL (variant EBNA1) virus strains were
exposed for 1 h to epitope peptide at concentrations mediating
half-maximal recognition, then washed several times and either
fixed immediately for T cell assay, or cultured in standard medium
then harvested and fixed for assay at later times. For assays
measuring the continued supply of complexes to the surface from
intracellular sources, we used an acid-stripping protocol that
preliminary work confirmed would completely remove both MHC
I- and MHC II-bound epitope peptides without affecting cell
viability ([35] and L. Mackay, unpublished observations). Cells
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citrate/phosphate buffer (0.131 M citric acid, 0.066 M
Na2HPO4), pH 3.1, for 20 min on ice before neutralization by
addition of excess standard medium. Stripped target cells were
then washed several times and an aliquot of cells fixed immediately
for T cell assay, while the remaining cells were re-cultured in
standard medium, then harvested and fixed for assay at later times.
Supporting Information
Table S1 T cell epitopes used as indices of antigen presentation
Found at: doi:10.1371/journal.ppat.1000699.s001 (0.01 MB PDF)
Figure S1 CD8
+ T cell recognition of EBNA1 and E1dGA early
post-induction. Results of a similar experiment to those shown in
Figure 3 but focusing on CD8 epitope presentation in the first 12 h
following induction of pEBNA1-tet- and pE1dGA-tet LCLs
(B*3501-positive) with dox at 25 ng/ml (left panels) and 100 ng/
ml dox (right panels). Cells, harvested at hourly intervals, were
fixed and assayed for recognition by HPV epitope-specific CD8
+ T
cells. (A) Levels of recognition, expressed as IFNc release, are
shown for the pEBNA1-tet (black line) and pE1dGA-tet (blue line)
LCLs; each assay included the appropriate long-term dox-induced
LCL as a control (lt dox, open circles). Values are means of
triplicate wells with SD always ,5%. (B) Levels of recognition of
the above targets, now expressed as a percentage of maximum
IFNc release seen with the appropriate long-term dox-induced
LCL. Similar results were obtained on two occasions.
Found at: doi:10.1371/journal.ppat.1000699.s002 (0.06 MB PDF)
Figure S2 T cell recognition assays involving target cell mixtures.
(A) Assays conducted using T cell clones specific for the CD8
epitope IVT/A*1101 and for the CD4 epitope ILR/DRB4*01,
both in EBNA3B. A dox-induced pEBNA3B-tet ‘‘donor’’ LCL [D]
expressing EBNA3B but A*1101, DRB4*01-negative was co-
cultured 1:1 for 7 days with a ‘‘recipient’’ EBNA3B-KO virus-
transformed LCL [R] which was A*1101, DRB4*01-positive,
producing the target cell mixture [D+R]. The D and R lines
cultured separately served as negative control targets, the D+R co-
culture pre-exposed to the epitope peptides immediately before the
T cell assay served as a positive control target. (B) Similar assays
conducted using T cell clones specific for the CD8 epitope HPV/
B*3501 and for the CD4 epitope VYG/DRB*11, both in EBNA1.
Here a dox-induced pEBNA1-tet LCL lacking the B*3501 and
DRB*11 alleles was the donor, and a CKL virus-transformed LCL
positive for the B*3501 and DRB*11 alleles was the recipient.
Recognition (mean of triplicate values +/2 SD) is expressed as
IFNc units/ml detected in assay supernatant by ELISA. Similar
patterns ofresultswereobtainedonthreeoccasions,and alsousinga
pE1dGA-tet LCL as the donor. (C) Culture supernatants were
harvested from 4 day-old cultures of a B95.8 virus-transformed
MHC mis-matched LCL (expressing cognate EBNA1) and, as a
control, of the EBV-negative B lymphoma cell line BJAB, both
grown in serum-free AIM-V medium as described [20]. Superna-
tants were concentrated 25-fold and then added to a DRB1*11-
positive CKL virus-transformed LCL. After overnight incubation,
supernatant-exposed (and untreated cells as a control) were washed
and used as targets for recognition by CD4
+ T cells specific for the
EBNA1-derived DRB1*11/VYG epitope. MHC-matched
(DRB1*11-positive) and MHC mis-matched (DRB1*11-negative)
B95.8 virus-transformed LCLs served as positive and negative
control targets respectively. Results are expressed as above.
Found at: doi:10.1371/journal.ppat.1000699.s003 (0.07 MB PDF)
FigureS3 Half-lifeofMHC-peptidecomplexesonthecellsurface
in relation to T cell recognition of transfected lines following dox
removal. Representative results from further peptide pulsing
experiments of the kind shown in Figure 7, now using (A) a
different E3B-KO virus-transformed LCL (A*1101, DRB3*0201-
positive) loaded with the relevant epitope peptides, then washed and
used as targets up to 192h later with T cells specific for the AVF/
A*1101 CD8 epitope and the QAP/DRB3*0201 CD4 epitope,
both from EBNA3B, and (B) a different CKL virus-transformed
LCL (B*07, DQB1*06-positive) peptide loaded and washed as
above, then used as targets for T cells specific for the IPQ/B*07
CD8 epitope and for the GLR/DQB1*06 CD4 epitope, both from
EBNA1. Experimental controls included and expression of results is
as described in Figure 7. Values are means of triplicate wells with
SD always ,5%. Similar results were obtained on three occasions.
Found at: doi:10.1371/journal.ppat.1000699.s004 (0.07 MB PDF)
Figure S4 Recovery of T cell recognition of transfected lines
following dox removal and stripping of cell surface peptides.
Representative results from a peptide stripping experiment of the
kind shown in Figure 8, using target LCLs removed from 25 ng/ml
dox. This experiment used (A) a different long-term dox-induced
pE3B-tet LCL (A*1101, ILR/DRB4*01-positive) washed free of
dox and used, either immediately (time 0 h) or up to 192 h later, as
a target for recognition by T cells specific for the IVT/A*1101 CD8
epitope and the ILR/DRB4*01 CD4 epitope, both from EBNA3B,
and (B) a different long-term dox-induced pEBNA1-tet LCL
(B*3501, DRB1*11-positive) washed free of dox as above and
assayed with T cells specific for the HPV/B*3501 CD8 epitope and
the VYG/DRB1*11 CD4 epitope, both from EBNA1. Results are
shown for cells stripped of cell surface peptides either immediately
after dox removal (0 h, blue line) or 48 h later (red line), then re-
cultured. Targets were fixed immediately before the assay. Results
for parallel cultures of non-stripped target cells, either left in dox (lt-
dox, grey line) or removed from dox at time 0 h as above (blackline)
are shown for comparison. Values are means of triplicate wells with
SD always ,5%. Similar results were obtained on three occasions.
Found at: doi:10.1371/journal.ppat.1000699.s005 (0.12 MB PDF)
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